(HealthDay News) – Ultra-early intravenous thrombolysis increases the likelihood of an excellent outcome in patients with moderate and mild stroke symptoms, according to research published online Aug. 22 in Stroke.
Daniel Strbian, MD, PhD, from the Helsinki University Central Hospital in Finland, and colleagues analyzed prospectively collected data from 6,856 consecutive ischemic stroke patients who received intravenous thrombolysis in 10 European stroke centers.
The researchers found that shorter onset-to-treatment time was significantly associated with an excellent outcome. Onset-to-treatment time was ≤90 minutes in every fifth patient and these patients had lower frequency of intracranial hemorrhage. Onset-to-treatment time of ≤90 minutes was also associated with an excellent outcome in patients with National Institutes of Health Stroke Scale (NIHSS) 7–12 (odds ratio, 1.37), but not in patients with baseline NIHSS >12 (odds ratio, 1; P=0.99) or baseline NIHSS of 0–6 (odds ratio, 1.04; P=0.8), when adjusting for age, sex, admission glucose level, and year of treatment. There was no association between ultra-early treatment and mortality.
“Intravenous thrombolysis within 90 minutes is, compared with later thrombolysis, strongly and independently associated with excellent outcome in patients with moderate and mild stroke severity,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.